Table 2. Comparison of SCAN-seq to current TGS base scRNA-seq methods.
Method | Amplification | Sequencing platform | No. of cells in a library | Cell capture efficiency | No. of UMIs per cell | No. of full-length genes per cell | Experiment cost per cell |
---|---|---|---|---|---|---|---|
SCAN-seq | Smart-seq2 | Nanopore | 10–48 | 80% | – | 8,000 | US$3 |
R2C2 [27–28] | Smart-seq2 | Nanopore | 1–96 | 64% | – | 532 | US$7 |
ScISOr-Seq [24] | 10x Genomics | NGS+Pacbio | >5,000 | 40% | 260 | 129 | US$0.3 |
ScNaUmi-seq [25] | 10x Genomics | NGS+Nanopore | 100–1,000 | 40% | 6047 | 2,427 | US$5 |
RAGE-seq [26] | 10x Genomics | NGS+Nanopore | 2,500–6,000 | 18.7% | – | TCR/BCR mRNA | US$0.5 |
BCR, B cell receptor; NGS, next generation sequencing; RAGE-seq, Repertoire and Gene Expression by Sequencing; R2C2, Rolling Circle Amplification to Concatemeric Consensus; SCAN-seq, single cell amplification and sequencing of full-length RNAs by Nanopore platform; ScISOr-Seq, single-cell isoform RNA-Seq; ScNaUmi-seq, Single-cell Nanopore sequencing with UMIs; scRNA-seq, single-cell RNA sequencing; TCR, T cell receptor; TGS, third-generation sequencing; UMI, unique molecular identifier.